Histogenics (HSGX) Stock Price, News & Analysis

Company Overview

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $1.01 to $1.15
• 50-Day Range: $0.16 to $3.07
• 52-Week Range: $0.08 to $1.43
• Volume: 7.01 million shs
• Average Volume: 9.06 million shs
• Market Capitalization: $97.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HSGX Stock Analysis - Frequently Asked Questions

How were Histogenics' earnings last quarter?

Histogenics Corp (NASDAQ:HSGX) posted its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.10.

When did Histogenics IPO?

Histogenics (HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What other stocks do shareholders of Histogenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Histogenics investors own include Interpace Biosciences (IDXG), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), Novavax (NVAX), SCYNEXIS (SCYX), Ocular Therapeutix (OCUL) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 8/09/2018
• Today: 6/25/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical Appliances & Supplies
• Sub-Industry: N/A
• Current Symbol: NASDAQ:HSGX
• CIK: 1372299
• Web: www.histogenics.com
• Phone: 781-547-7900
• Fax: N/A
• Employees: 49
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.64 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -34.96%
• Return on Assets: 18.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.05
• Quick Ratio: 4.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.01) per share
• Price / Book: -103.50

Miscellaneous

• Outstanding Shares: 94,599,000
• Free Float: N/A
• Market Cap: $97.91 million
• Optionable: Not Optionable
• Beta: 3.10